{"url_path":"/sec/caba/8-k/2026-06-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1759138/0001759138-26-000030-index.html","accession_number":"0001759138-26-000030","cik":"0001759138","ticker":"CABA","issuer_name":"Cabaletta Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1759138/0001759138-26-000030-index.html","primary_entity_key":"0001759138","primary_entity_name":"Cabaletta Bio, Inc."},"word_count":140,"has_tables":true,"body_markdown":"## Item 7.01 Regulation FD Disclosure.\n\nOn June 3, 2026, Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) issued a press release announcing new rese-cel data and development updates across the Company's autoimmune portfolio, including encouraging early preconditioning-free (\"PC-free\") lupus findings (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}